IL2 and colitis: Scientists have engineered a specific IL-2 monoclonal antibody (mAb), JES6-1, that selectively proliferates Tregs and demonstrates superior disease management in a mouse model of colitis, in comparison to a non-covalently linked complex of IL-2 and JES6-1 (121).